Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sep 13, 2011, 04:12 ET from Reportlinker

NEW YORK, Sept. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0611549/Anemia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Hardware,_Home_Improvement_&_Furnishing_Stores

Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Anemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Anemia Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Anemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Anemia Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anemia Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Anemia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Anemia Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anemia Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Anemia Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Anemia Therapeutics - Introduction 6

2.1 Overview 6

2.2 Etiology and Pathophysiology 7

2.3 Epidemiology 8

2.4 Symptoms 8

2.5 Diagnosis 9

2.5.1 Physical Examination 9

2.5.2 Complete Blood Count (CBC) 9

2.5.3 Other Tests and Procedures 10

2.6 Treatment and Management Pattern 10

2.6.1 Dietary Changes and Supplements 11

2.6.2 Medicines 11

2.6.3 Medical Procedures 11

2.7 GlobalData Pipeline Report Guidance 12

3 Anemia Therapeutics - Market Characterization 13

3.1 Anemia Therapeutics Market Size (2005-2010) – Global 13

3.2 Anemia Therapeutics Market Forecast (2010–2018) – Global 15

3.3 Anemia Therapeutics Market Size (2005-2010) – The US 17

3.4 Anemia Therapeutics Market Forecast (2010-2018) – The US 18

3.5 Anemia Therapeutics Market Size (2005-2010) – France 19

3.6 Anemia Therapeutics Market Forecast (2010-2018) – France 20

3.7 Anemia Therapeutics Market Size (2005-2010) – Germany 21

3.8 Anemia Therapeutics Market Forecast (2010-2018) – Germany 22

3.9 Anemia Therapeutics Market Size (2005-2010) – Italy 23

3.10 Anemia Therapeutics Market Forecast (2010-2018) – Italy 24

3.11 Anemia Therapeutics Market Size (2005-2010) – Spain 25

3.12 Anemia Therapeutics Market Forecast (2010-2018) – Spain 26

3.13 Anemia Therapeutics Market Size (2005-2010) – The UK 27

3.14 Anemia Therapeutics Market Forecast (2010–2018) – The UK 28

3.15 Anemia Therapeutics Market Size (2005-2010) – Japan 29

3.16 Anemia Therapeutics Market Forecast (2010-2018) – Japan 30

3.17 Drivers and Barriers for the Anemia Therapeutics Market 31

3.17.1 Drivers for the Anemia Market 31

3.17.2 Barriers for the Anemia Market 31

3.18 Opportunity and Unmet Need Analysis 32

3.18.1 Opportunity and Unmet Need for Erythropoietin Stimulating Agents (ESA) 32

3.18.2 Opportunity and Unmet Need for Iron Supplements: 33

3.19 Key Takeaway 33

4 Anemia Therapeutics Market - Competitive Assessment 34

4.1 Overview 34

4.2 Strategic Competitor Assessment 34

4.2.1 Competitor Assessment Within Different Therapeutic Categories Employed in Anemia Treatment: 35

4.3 Product Profile for the Major Marketed Products in the Anemia Market 37

4.3.1 Aranesp (darbepoetin alfa) 37

4.3.2 Mircera (methoxy polyethylene glycol-epoetin beta) 38

4.3.3 Biopoin/Eporatio (epoetin theta) 39

4.3.4 Epogen/Procrit/Eprex (epoetin alfa) 40

4.3.5 Epogin/Neorecormon (epoetin beta) 41

4.3.6 Bio-Similar Erythropoietins 41

4.3.7 Oral Iron Supplements 41

4.3.8 Feraheme (ferumoxytol) 42

4.3.9 Ferinject/Injectafer (ferric carboxymaltose) 43

4.3.10 Venofer/Fesin (iron sucrose) 44

4.3.11 Monofer (iron isomaltide) 44

4.3.12 Cosmofer/InFed/Ferrisat (iron dextran) 45

4.3.13 Ferrlecit (sodium ferricgluconate complex) 45

4.3.14 Immunosuppressive Agents 45

4.3.15 Vitamin Supplements 46

4.4 Key Takeaway 46

5 Anemia Therapeutics - Pipeline Assessment 47

5.1 Overview 47

5.2 Strategic Pipeline Assessment 47

5.3 Anemia Therapeutics Pipeline – Pipeline by Phase of Development 48

5.3.1 Anemia Therapeutics – Filed Pipeline 48

5.3.2 Anemia Therapeutics – Phase III Pipeline 49

5.3.3 Anemia Therapeutics – Phase II/III Pipeline 49

5.3.4 Anemia Therapeutics – Phase II Pipeline 50

5.3.5 Anemia Therapeutics – Phase I/II Pipeline 50

5.3.6 Anemia Therapeutics – Phase I Pipeline 50

5.3.7 Anemia Therapeutics – Preclinical Pipeline 51

5.3.8 Anemia Therapeutics – Discovery Pipeline 51

5.4 Anemia Therapeutics – Pipeline by Mechanism of Action 52

5.5 Technology Trends Analytic Framework 53

5.6 Anemia Therapeutics – Promising Drugs Under Clinical Development 54

5.7 Molecule Profile for Promising Drugs Under Clinical Development 55

5.7.1 Hematide (peginesatide) 55

5.7.2 ST10-021 56

5.7.3 Soluble Ferric Pyrophosphate (SFP) 57

5.8 Key Takeaway 58

6 Anemia Therapeutics - Clinical Trials Mapping 59

6.1 Clinical Trials by Country (US, EU5 and Japan) 59

6.2 Clinical Trials by Phase 60

6.3 Clinical Trials by Trial Status 61

6.4 Overall Sponsors 62

6.5 Prominent Sponsors 63

6.6 Top Companies Participating in Anemia Therapeutics Clinical Trials 64

7 Anemia - Strategic Assessment 65

7.1 Key Events Impacting the Future Market 65

7.2 Anemia Therapeutics - Implications for Future Market Competition 65

8 Anemia Therapeutics - Future Players 67

8.1 Introduction 67

8.2 Company Profiles 67

8.2.1 F. Hoffmann-La Roche Ltd. 67

8.2.2 Affymax, Inc.: 73

8.2.3 3SBio Inc.: 73

8.2.4 Kyowa Hakko Kirin Co., Ltd: 76

8.2.5 Shield Therapeutics 81

8.2.6 Pharmacosmos A/S 81

8.2.7 Amgen Inc. 82

8.2.8 Johnson & Johnson 86

8.2.9 Millennium - The Takeda Oncology Company 91

8.2.10 Galenica Ltd. 96

8.2.11 Rockwell Medical Technologies, Inc. 98

8.2.12 Other Companies in the Anemia Market 99

9 Anemia Therapeutics - Licensing and Partnership Deals 103

10 Anemia Therapeutics - Appendix 107

10.1 Market Definitions 107

10.2 Abbreviations 107

10.3 Methodology 108

10.3.1 Coverage 108

10.3.2 Secondary Research 108

10.3.3 Forecasting 108

10.3.4 Primary Research 111

10.3.5 Expert Panel Validation 111

10.4 Contact Us 111

10.5 Disclaimer 111

10.6 Bibliography 112

1.1 List of Tables

Table 1: Anemia Therapeutics Market, Global, Market ($bn), 2005–2010 13

Table 2: Anemia Therapeutics Market, Global, Forecast ($bn), 2010–2018 15

Table 3: Anemia Therapeutics Market, The US, Market ($bn), 2005–2010 17

Table 4: Anemia Therapeutics Market, The US, Forecast ($bn), 2010–2018 18

Table 5: Anemia Therapeutics Market, France, Market ($m), 2005–2010 19

Table 6: Anemia Therapeutics Market, France, Forecast ($m), 2010–2018 20

Table 7: Anemia Therapeutics Market, Germany, Market ($m), 2005–2010 21

Table 8: Anemia Therapeutics Market, Germany, Forecast ($m), 2010–2018 22

Table 9: Anemia Therapeutics Market, Italy, Market ($m), 2005–2010 23

Table 10: Anemia Therapeutics Market, Italy, Forecast ($m), 2010–2018 24

Table 11: Anemia Therapeutics Market, Spain, Market ($m), 2005–2010 25

Table 12: Anemia Therapeutics Market, Spain, Forecast ($m), 2010–2018 26

Table 13: Anemia Therapeutics Market, The UK, Market ($m), 2005–2010 27

Table 14: Anemia Therapeutics Market, The UK, Forecast ($m), 2010–2018 28

Table 15: Anemia Therapeutics Market, Japan, Market ($m), 2005–2010 29

Table 16: Anemia Therapeutics Market, Japan, Forecast ($m), 2010–2018 30

Table 17: Anemia Therapeutics – Filed Pipeline, 2011 48

Table 18: Anemia Therapeutics – Phase III Pipeline, 2011 49

Table 19: Anemia Therapeutics – Phase II/III Pipeline, 2011 49

Table 20: Anemia Therapeutics – Phase II Pipeline, 2011 50

Table 21: Anemia Therapeutics – Phase I/II Pipeline, 2011 50

Table 22: Anemia Therapeutics – Phase I Pipeline, 2011 50

Table 23: Anemia Therapeutics – Preclinical Pipeline, 2011 51

Table 24: Anemia Therapeutics – Discovery Pipeline, 2011 51

Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart 52

Table 26: Anemia Therapeutics – Most Promising Drugs Under Clinical Development, 2011 54

Table 27: Anemia Therapeutics – Clinical Trials by Country, 2011 59

Table 28: Anemia Therapeutics - Clinical Trials by Phase, 2011 60

Table 29: Anemia Therapeutics - Clinical Trials by Status, 2011 61

Table 30: Anemia Therapeutics - Prominent Sponsors, 2011 63

Table 31: Anemia Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 64

Table 32: F. Hoffmann-La Roche Ltd. - Hematology Pipeline 69

Table 33: F. Hoffmann-La Roche Ltd. - Anemia Pipeline 69

Table 34: F. Hoffmann-La Roche Ltd. – Deals 69

Table 35: Affymax, Inc. - Hematology Pipeline 73

Table 36: Affymax, Inc. - Anemia Pipeline 73

Table 37: 3SBio Inc. – Hematology Pipeline Portfolio, 2011 74

Table 38: 3SBio Inc. – Anemia Pipeline 75

Table 39: 3SBio Inc. – Deals 75

Table 40: Kyowa Hakko Kirin Co., Ltd. – Hematology pipeline products, 2011 78

Table 41: Kyowa Hakko Kirin Co., Ltd. – Anemia Pipeline 78

Table 42: Kyowa Hakko Kirin Co., Ltd. – Deals 79

Table 43: Shield Therapeutics – Hematology Pipeline 81

Table 44: Pharmacosmos A/S – Hematology Pipeline 81

Table 45: Pharmacosmos A/S – Deals 82

Table 46: Amgen Inc. – Hematology Pipeline 83

Table 47: Amgen Inc. – Anemia Pipeline 83

Table 48: Amgen Inc. - Deals 84

Table 49: Johnson & Johnson – Hematology Pipeline 87

Table 50: Johnson & Johnson – Deals 87

Table 51: Millennium: The Takeda Oncology Company – Hematology Pipeline 92

Table 52: Millennium: The Takeda Oncology Company – Deals 92

Table 53: Galenica Therapeutics- Hematology Pipeline, 2011 97

Table 54: Galenica Ltd- Deals, 2011 97

Table 55: Rockwell Medical Technologies, Inc. - Hematology Pipeline, 2011 99

Table 56: Other Future Players in the Anemia Therapeutics Market 99

Table 57: Anemia Therapeutics, Licensing and Partnership Deals 103

1.2 List of Figures

Figure 1: Physiologic Classification of Anemia 6

Figure 2: Classification of Anemia According to World Health Organization (WHO) - International Classification of Disease (ICD) 7

Figure 3: Laboratory Tests Conducted in Complete Blood Count (CBC) Diagnostic Test 9

Figure 4: Therapy Options for Anemia 10

Figure 5: Anemia Therapeutics Market, Global, Revenue ($bn), 2005–2010 13

Figure 6: Anemia Therapeutics, Market Share ($m), 2005 14

Figure 7: Anemia Therapeutics Market, Global, Forecast ($bn), 2010–2018 15

Figure 8: Anemia Therapeutics, Market Share ($m), 2010 16

Figure 9: Anemia Therapeutics Market, The US, Market ($bn), 2005–2010 17

Figure 10: Anemia Therapeutics Market, The US, Forecast ($bn), 2010–2018 18

Figure 11: Anemia Therapeutics Market, France, Market ($m), 2005–2010 19

Figure 12: Anemia Therapeutics Market, France, Forecast ($m), 2010–2018 20

Figure 13: Anemia Therapeutics Market, Germany, Market ($m), 2005–2010 21

Figure 14: Anemia Therapeutics Market, Germany, Forecast ($m), 2010–2018 22

Figure 15: Anemia Therapeutics Market, Italy, Market ($m), 2005–2010 23

Figure 16: Anemia Therapeutics Market, Italy, Forecast ($m), 2010–2018 24

Figure 17: Anemia Therapeutics Market, Spain, Market ($m), 2005–2010 25

Figure 18: Anemia Therapeutics Market, Spain, Forecast ($m), 2010–2018 26

Figure 19: Anemia Therapeutics Market, The UK, Market ($m), 2005–2010 27

Figure 20: Anemia Therapeutics Market, The UK, Forecast ($m), 2010–2018 28

Figure 21: Anemia Therapeutics Market, Japan, Market ($m), 2005–2010 29

Figure 22: Anemia Therapeutics Market, Japan, Forecast ($m), 2010–2018 30

Figure 23: Opportunity and Unmet Need for Erythropoietin Stimulating Agents in the Anemia Therapeutics Market, 2011 32

Figure 24: Opportunity and Unmet Need for Iron Supplements in the Anemia Therapeutics Market, 2011 33

Figure 25: Anemia Therapeutics – Strategic Competitor Assessment of Erythropoietin Stimulating Agents, 2011 35

Figure 26: Anemia Therapeutics – Strategic Competitor Assessment of Iron Supplements, 2011 36

Figure 27: Anemia Therapeutics – Pipeline by Phase of Development, 2011 48

Figure 28: Anemia Therapeutics – Pipeline by Mechanism of Action, 2011 52

Figure 29: Anemia Therapeutics – Technology Trends Analytics Framework, 2011 53

Figure 30: Anemia Therapeutics – Technology Trends Analytics Framework – Description, 2011 54

Figure 31: Anemia Therapeutics – Clinical Trials by Country, 2011 59

Figure 32: Anemia Therapeutics - Clinical Trials by Phase, 2011 60

Figure 33: Anemia Therapeutics - Clinical Trials by Status, 2011 61

Figure 34: Anemia Therapeutics - Overall Sponsors, 2011 62

Figure 35: Anemia Therapeutics - Prominent Sponsors, 2011 63

Figure 36: Anemia Therapeutics Market - Top Companies Participating in Therapeutics Clinical Trials, 2011 64

Figure 37: Anemia Market, Drivers and Restraints, 2011 65

Figure 38: Implications for Future Market Competition in Anemia Market, 2011 65

Figure 39: Anemia Therapeutics – Pipeline by Company, 2011 67

Figure 40: GlobalData Market Forecasting Model 110

Companies mentioned

F. Hoffmann-La Roche Ltd.

Affymax, Inc.:

3SBio Inc.:

Kyowa Hakko Kirin Co., Ltd:

Shield Therapeutics

Pharmacosmos A/S

Amgen Inc.

Johnson & Johnson

Millennium - The Takeda Oncology Company

Galenica Ltd.

Rockwell Medical Technologies, Inc.

To order this report:

Hardware, Home Improvement & Furnishing Stores Industry: Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Hardware, Home Improvement & Furnishing Stores Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com